logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions.

    Article - En anglais

    Pharmacy benefit management companies (PBMs) have evolved over the past decade in response to the increased demand for health care cost containment.

    Their activities include the implementation of drug formularies and the negotiation of rebates from manufacturers.

    Our analysis of this industry is based on interviews and materials provided by the top five ranked PBM companies which account for over 80% of beneficiaries covered within formulary plans.

    The formularies of these companies are relatively inclusive, but they are becoming more restrictive over time.

    At present the use of cost-effectiveness (C-E) studies in the formulary decisions of PBMs has been limited.

    In this regard, the surveyed PBMs emphasized that most C-E studies have not compared therapeutic substitutes in populations with characteristics that are similar to those of their clients.

    Pharmacy benefit management companies also have had strong incentives to focus narrowly on drug costs because they typically manage drug benefits on a « carved-out » basis.

    However, PBMs anticipate a growing future role in the integrated management of patient care (disease management) for certain high cost chronic diseases and conditions.

    All of the leading firms we surveyed have disease management programs in development.

    The importance of C-E studies to PBM decisions is expected to increase significantly as disease management programs are implemented. (...)

    Mots-clés Pascal : Industrie pharmaceutique, Bénéfice, Analyse coût efficacité, Prise décision, Prescription médicale, Stratégie, Economie santé, Etats Unis, Amérique du Nord, Amérique

    Mots-clés Pascal anglais : Pharmaceutical industry, Profit, Cost efficiency analysis, Decision making, Medical prescription, Strategy, Health economy, United States, North America, America

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0432492

    Code Inist : 002B30A01B. Création : 19/12/1997.